Angiomyolipomas: Understanding, Diagnosing, and Treating This Kidney Tumor | FKMD

Angiomyolipomas: Understanding, Diagnosing, and Treating This Kidney Tumor

An angiomyolipoma (AML) is a benign (non-cancerous) tumor most commonly found in the kidneys. Though not usually life-threatening, these tumors can grow large, rupture, and cause serious bleeding. At FKMD, we provide patients with advanced, image-guided treatment options—often avoiding invasive surgery altogether.

In this blog, we’ll explain what angiomyolipomas are, who they affect, how they are diagnosed, and why embolization—a minimally invasive technique—can be a safe and effective alternative to traditional surgery.

What Is an Angiomyolipoma?

Angiomyolipomas are made up of three types of tissue: blood vessels, smooth muscle, and fat. These tumors are usually found in the kidney and can occur either on their own (sporadically) or as part of a genetic condition called tuberous sclerosis complex (TSC).

Most AMLs are discovered during imaging tests done for other reasons. They are more common in women, typically diagnosed between the ages of 30 and 50, and often grow slowly over time. While many are small and cause no symptoms, others can enlarge and put the patient at risk of internal bleeding.

Symptoms of Angiomyolipomas

  • Flank or abdominal pain
  • Blood in the urine (hematuria)
  • Palpable mass in the abdomen
  • Nausea or vomiting
  • Sudden severe pain if the tumor ruptures

Ruptured angiomyolipomas are a medical emergency and can lead to life-threatening bleeding. That’s why early detection and monitoring are important.

How Are AMLs Diagnosed?

  • Ultrasound: A first-line imaging test to identify fatty tissue in the kidney
  • CT scan: Provides detailed images to assess tumor size and bleeding risk
  • MRI: Helps distinguish AMLs from other kidney tumors or masses

Who Is at Risk?

  • Female gender
  • Middle age (30–50 years)
  • Tuberous sclerosis complex (TSC)
  • History of other kidney abnormalities

When Is Treatment Needed?

Treatment is often recommended if the AML:

  • Is larger than 4 cm
  • Is growing rapidly
  • Causes symptoms or bleeding
  • Is associated with TSC

Minimally Invasive Treatment: Embolization

At FKMD, we offer selective arterial embolization—a safe and effective way to treat AMLs without surgery. A thin catheter is guided into the blood vessels feeding the tumor. Tiny particles are injected to block blood flow, causing the tumor to shrink and lowering the risk of bleeding.

  • Minimally invasive—no surgical incision
  • Preserves healthy kidney tissue
  • Usually performed outpatient with fast recovery
  • Lower risk of complications than open surgery

What to Expect During the Procedure

Embolization is performed under image guidance (fluoroscopy or CT) with local anesthesia and mild sedation. The procedure typically takes 1 to 2 hours. Most patients go home the same day and return to normal activities within a few days.

Alternative Treatments

  • Partial nephrectomy: Used for very large or complex AMLs
  • mTOR inhibitors: Medications like everolimus, especially in patients with TSC
  • Active surveillance: For small, stable AMLs without symptoms

Why Choose FKMD?

FKMD specializes in minimally invasive, image-guided therapies. Our interventional radiology team works closely with your referring providers to ensure comprehensive care, personalized treatment, and long-term follow-up.

Schedule a Consultation Today

If you’ve been diagnosed with an angiomyolipoma, FKMD offers safe, effective, and non-surgical treatment options that can reduce your risks and preserve your kidney function.

📞 Call us today at 650-404-8445 to schedule your consultation.